Abbott Eyes November For Xience FDA Panel Review
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories has penciled in Nov. 29 to present its Xience V everolimus-eluting stent to an FDA advisory panel, the company said Sept. 24